The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. Academic Article

abstract

• Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up-regulation of growth factor expression and increased shedding of syndecan-1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan-1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan-1 axis hold promise for blocking the aggressive behaviour of cancer.

authors

• Purushothaman, Anurag

published proceedings

• FEBS J

altmetric score

• 6.25

author list (cited authors)

• Ramani, V. C., Purushothaman, A., Stewart, M. D., Thompson, C. A., Vlodavsky, I., Au, J., & Sanderson, R. D.

citation count

• 153

complete list of authors

• Ramani, Vishnu C||Purushothaman, Anurag||Stewart, Mark D||Thompson, Camilla A||Vlodavsky, Israel||Au, Jessie L-S||Sanderson, Ralph D

publication date

• May 2013

publisher

• Wiley  Publisher

published in

• The FEBS Journal  Journal

keywords

• Animals
• Antineoplastic Agents
• Biomimetic Materials
• Cell Nucleus
• Enzyme Activation
• Enzyme Inhibitors
• Exosomes
• Gene Expression Regulation, Neoplastic
• Glucuronidase
• Heparitin Sulfate
• Hepatocyte Growth Factor
• Humans
• Neoplasms
• Signal Transduction
• Syndecan-1

PubMed Central ID

• 23374281

Digital Object Identifier (DOI)

• 10.1111/febs.12168

start page

• 2294

end page

• 2306

volume

• 280

issue

• 10

URL

• http://dx.doi.org/10.1111/febs.12168